ValueQ3, 24Q4, 24Q1, 25Q2, 25Q3, 25TTMSelling/general/admin expenses6.97 M8.25 M7.84 M7.71 M7.73 M31.53 MResearch & development12.03 M12.88 M14.33 M16.62 M20.34 M64.17 MOperating income-18.63 M-44.98 M-21.83 M-24.04 M-27.86 M-118.72 MNon-Operating Income, Total3.51 M2.72 M3.65 M2.04 M1.89 M10.3 MInterest expense, net of interest capitalized——————Non-Operating Income, excl. Interest Expenses3.51 M2.72 M2.25 M2.04 M1.89 M8.9 MUnusual income/expense——1.4 M00—Pretax income-15.12 M-42.27 M-18.18 M-22 M-25.97 M-108.41 MEquity in earnings0-2 000-1 00000-3 000Taxes035.92 M————Non-controlling/minority interest——————After tax other income/expense—170 K-138 K-84 K-14 K-66 KNet income before discontinued operations-15.12 M-40.17 M-18.18 M-22 M-25.97 M-106.31 MDiscontinued operations000514 K0514 KNet income-15.12 M-40.17 M-18.18 M-21.48 M-25.97 M-105.8 MDilution adjustment——————Preferred dividends——————Diluted net income available to common stockholders15.12 M40.17 M18.18 M21.48 M25.97 M105.8 MBasic earnings per share (Basic EPS)-0.19-0.59-0.25-0.29-0.35-1.48Diluted earnings per share (Diluted EPS)-0.19-0.59-0.25-0.29-0.35-1.48Average basic shares outstanding62.29 M64.42 M72.36 M73.3 M73.64 M283.72 MDiluted shares outstanding62.29 M64.42 M72.36 M73.3 M73.64 M283.72 MEBITDA——————EBIT——————Cost of revenue——————Other cost of goods sold——————Depreciation & amortization (cash flow)669 K7 000————
Perspective Therapeutics Inc
Isoray Inc. is a national isotope-based medical company and the sole producer of Cesium brachytherapy sources, which are expanding brachytherapy treatments for difficult to treat cancers. Isoray is a registered manufacturer with the FDA and holds multiple 510 clearances for brachytherapy devices. The brachytherapy isotopes are sold under the brandname Blu.
The company went public in 2005. Isoray’s corporate headquarters is located at 350 Hills Street, Suite 106, Richland WA 99354.